Use of HTK solution in kidney preservation

Transplantation Proceedings

Volumn 35, Issue 2, 2003, Pages 766-

  Trushkov, S ^a   Bicans, J ^a   Shevelev, V ^a   Jushinskis, J ^a   Suhorukov, V ^a   Rozental, R ^a  

^a PAULS STRADINS CLINICAL UNIVERSITY HOSPITAL   (Latvia)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; CREATININE; CYCLOSPORIN A; EURO COLLINS SOLUTION; HTK SOLUTION; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID;

ADOLESCENT; ADULT; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; GRAFT SURVIVAL; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DONOR; KIDNEY FUNCTION; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; KIDNEY PRESERVATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; URINE VOLUME;

EID: 0037339141     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0041-1345(03)00033-2     Document Type: Conference Paper

References (3)

1. Mühlbacher F., Langer F., Mittermayer C. Transplant Proc. 31:1999;2069.
2. Ploeg R.J., van Bockel J.H., Langendijk P.T., et al. Lancet. 18:1992;129.
3. de Boer J., Smits J.M.A., de Meester J., et al. Transplant Proc. 31:1999;2065.